PulmoXen (dornase alfa biobetter) / Pharmsynthez, Xenetic Biosci - LARVOL DELTA

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses (Xenetic Biosciences Press Release) - "Using bioluminescent imaging, researchers observed that a single injection of DNase I (10 mg/kg) effectively suppressed B16-EGFR lung metastasis at early stages compared to vehicle controls. However, while DNase I demonstrated efficacy in reducing tumor growth, it did not significantly improve survival when administered alone. The combination treatment of DNase I with murine EGFR-CAR T cells led to a marked suppression of tumor burden, a decrease in the number of metastatic foci, and substantial prolongation of survival compared to CAR T cell monotherapy. This therapeutic enhancement was associated with an increase in tumor-infiltrating T and CAR T cells, indicating improved immune engagement. Analysis of the CD8 T cell population from DNase I-treated groups revealed a notable decrease in PD-1 and TIM-3 expression, markers of T cell exhaustion, suggesting that DNase I effectively mitigates the immunosuppressive effects of the tumor microenvironment (TME)."

Preclinical • Melanoma • Oncology